Bristol-Myers dismisses Celgene investors' drug delay lawsuit

By Lauren Berg (September 30, 2024, 9:24 p.m. EDT) — A New York federal judge on Monday rejected UMB Bank's claims that Bristol-Myers Squibb improperly delayed the FDA's approval of a cancer treatment to avoid paying shareholders $6.4 billion from a takeover of Celgene Corp. owed in 2019, on the grounds that the bank had no legal standing….

Law360 is there, so you are too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments, so you can act quickly and confidently. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features like

• Daily newsletters
• Expert analysis
• Mobile app
• Advanced search
• Information about the judge
• Real-time alerts
• Over 450,000 searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.